Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report.
- Published in:
- Clinical Pharmacology, 2011, v. 3, p. 45
- By:
- Publication type:
- Article
Works matching IS 11791438 AND DT 2011 AND VI 3
Results: 7
1
2
Detemir as a once-daily basal insulin in type 2 diabetes.
- Published in:
- Clinical Pharmacology, 2011, v. 3, p. 27
- By:
- Publication type:
- Article
3
Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions.
- Published in:
- Clinical Pharmacology, 2011, v. 3, p. 39
- By:
- Publication type:
- Article
4
Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome.
- Published in:
- Clinical Pharmacology, 2011, v. 3, p. 5, doi. 10.2147/CPAA.S17904
- By:
- Publication type:
- Article
5
A case of cephalothin-associated urolithiasis.
- Published in:
- Clinical Pharmacology, 2011, v. 3, p. 1, doi. 10.2147/CPAA.S16516
- By:
- Publication type:
- Article
6
Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole.
- Published in:
- Clinical Pharmacology, 2011, v. 3, p. 13
- By:
- Publication type:
- Article
7
Drug-resistant tuberculosis: emerging treatment options.
- Published in:
- Clinical Pharmacology, 2011, v. 3, p. 51
- By:
- Publication type:
- Article